Tag Archives: LongTerm

ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah

SAN DIEGO—Gilead and Novartis are working to ramp up launches of their slow-starting CAR-T drugs, and both companies are hoping longer-term follow-up data will help do the trick. Sunday at the American Society of Hematology (ASH) annual meeting, Gilead’s Kite unit rolled out two-year data from the Zuma-1 study that won Yescarta its October 2017 approval… Read More »